The yearly MetaSystems Distributor Meeting (DM), brought into life in 2002 as a platform to gather all international partners of MetaSystems and other members of the global MetaSystems family, just ended last week. The DM is being organized in turns by MetaSystems Headquarters, MetaSystems USA (MGI), and MetaSystems Asia. Since MGI is celebrating its 25th anniversary in 2018 they decided to choose a special location: Nassau, The Bahamas!
Translocation/Dual Fusion Probe
- Order Number
- Package Size
- 100 µl
Several recurrent balanced translocations and inversions, and their variants, are
recognized in the WHO category acute myeloid leukemia (AML) with recurrent genetic abnormalities. Furthermore, several cytogenetic abnormalities are considered sufficient to establish the WHO diagnosis of AML with myelodysplasia-related features when 20% or more blood or marrow blasts are present.
The t(8;21)(q22;q22) is the most common translocation in de novo AML occurring in up to 20 % of adult and 40 % of pediatric cases of AML. The translocation fuses AML1 (RUNX1) with ETO (RUNX1T1) to produce the AML1/ETO fusion gene located on the derivative 8 chromosome. The prognosis after intensive chemotherapy is better for these patients than for the majority of AML patients.
- Acute Myelogenous Leukemia (AML)
Normal Cell: Two green (2G) and two orange (2O) signals.
Aberrant Cell (typical results):
One green (1G), one orange (1O), and two green-orange signals (2GO).
- Levanon et al (2001) Gene 262:23-33
- Varella-Garcia et al (2001) Leukemia 15:1408-1414
- ? Zhang et al (2002) PNAS 99: 3070-3075